SUMMARY  

The following information has been provided in response to your unsolicited request. The information contained in this response is not intended as an endorsement or promotion of any usage. In order to streamline this bibliography, some citations are not listed. This product is an investigational agent and is not approved by the Food and Drug Administration (FDA) in the United States. For information on ongoing clinical trials for our products, please visit www.clinicaltrials.gov.

Johnson & Johnson Phase 3 Clinical Studies

ICONIC-ADVANCE 1 (NCT06143878) & ICONIC-ADVANCE 2 (NCT06220604)

Key Publication:

Gold L, Armstrong A, Bissonnette R, et al. Once-daily oral icotrokinra versus placebo and once-daily oral deucravacitinib in participants with moderate-to-severe plaque psoriasis (ICONIC-ADVANCE 1 & 2): two phases 3, randomized, placebo-controlled and active-comparator-controlled trials. Lancet. 2025; 406: 1363-1374.

Related presentations:

• Gold L, Armstrong A, Bissonnette R, et al. Icotrokinra demonstrated superior responses compared with placebo and deucravacitinib in the treatment of moderate-to-severe plaque psoriasis: results through week 24 of the phase 3 ICONIC-ADVANCE 1 and ICONIC-ADVANCE 2 studies. Oral Presentation presented at: The European Academy of Dermatology and Venereology Congress (EADV); September 17-20, 2025; Paris, France.

ICONIC-LEAD (NCT06095115)

Key Publication:

Bissonnette R, Soung J, Hebert AA, et al. Oral icotrokinra for plaque psoriasis in adults and adolescents. N Engl J Med. 2025;393:1784-1795.

Related presentations:

• Soung J, Cui Y, Bissonnette R, et al. Maintenance of response with icotrokinra, a targeted oral peptide, for the treatment of moderate-to-severe plaque psoriasis: randomized treatment withdrawal in adults (weeks 24-52) and continuous treatment in adolescents (through week 52) from the phase 3, ICONIC-LEAD trial. Oral Presentation presented at: The European Academy of Dermatology and Venereology Congress (EADV); September 17-20, 2025; Paris, France.
• Cantero A, Soung J, Ehst B, et al. High-level improvements in psoriasis area and severity index with icotrokinra in participants with moderate-to-severe plaque psoriasis: results through week 24 of the phase 3 ICONIC-LEAD study. Poster presented at: The European Academy of Dermatology and Venereology Congress (EADV); September 17-20, 2025; Paris, France.
• Angsana J, Polak M, Nischal S, et al. Early systemic and skin pharmacodynamic effects of icotrokinra in participants with moderate-to-severe plaque psoriasis: results through week 24 of the phase 3, ICONIC-LEAD study. Poster presented at: The European Academy of Dermatology and Venereology Congress (EADV); September 17-20, 2025; Paris, France.
• Soung J, Hong C, Ehst B, et al. Treatment of plaque psoriasis involving high-impact sites with icotrokinra: subgroup analyses of the phase 3, ICONIC-LEAD trial. Poster presented at: The American Academy of Dermatology (AAD) Innovation Academy; July 10-13, 2025; Chicago, IL.
• Eichenfield L, Galimberti R, Hebert A, et al. Icotrokinra, a novel targeted oral peptide (IL-23R-inhibitor) in adolescents with moderate-to-severe plaque psoriasis: results of subgroup analyses from a phase 3, randomized, double-blind, placebo-controlled study (ICONIC-LEAD). Oral Presentation presented at: The World Congress of Pediatric Dermatology (WCPD); April 8-11, 2025; Buenos Aires, Argentina.
• Bissonnette R, Soung J, Herbert A, et al. Icotrokinra, a targeted oral peptide that selectively blocks the IL-23 receptor, for the treatment of moderate-to-severe plaque psoriasis: results through week 24 of the phase 3, randomized, double-blind, placebo-controlled ICONIC-LEAD trial. Poster presented at: The American Academy of Dermatology (AAD) Annual Meeting; March 7-11, 2025; Orlando, FL.

ICONIC-TOTAL (NCT06095102)

Key Publication:

Gooderham M, Lain E, Bissonnette R, et al. Targeted oral peptide icotrokinra for psoriasis involving high-impact sites. NEJM Evid. 2025;4(12).

Related Presentations:

• Lain E, Warren R.B, Gooderham M, et al. Durability of response to the targeted oral peptide icotrokinra for high-impact site psoriasis: 1-year ICONIC-TOTAL findings. Poster presented at: Fall Clinical Dermatology Conference, October 23-26, 2025; Las Vegas, NV.
• Gooderham M, Lain E, Bissonnette R, et al. Phase 3 results from an innovative trial design of treating plaque psoriasis involving difficult-to-treat, high-impact sites with icotrokinra, a targeted oral peptide that selectively inhibits the IL-23-receptor. Poster presented at: The Society of Investigative Dermatology (SID) annual meeting, May 7-10, 2025, San Diego, CA.

Johnson & Johnson Phase 2

FRONTIER-1  (NCT05223868)

Key Publication:

Bissonnette R, Pinter A, Ferris L. An oral interleukin-23–receptor antagonist peptide for plaque psoriasis. N Engl J Med. 2024; 390:510-21.

Related Presentations:

• Merola J, Mease P, Coates L, et al. Icotrokinra, a first-in-class, targeted oral peptide, in participants with psoriatic disease: exploratory assessments from a phase 2 psoriasis study informing a phase 3 clinical program in psoriatic arthritis. Poster presented at: The European Alliance of Associations for Rheumatology (EULAR); June 11-14, 2025; Barcelona, Spain.
• Bissonnette R, Pinter A, Ferris L, et al. A phase 2, randomized, placebo-controlled, dose-ranging study of oral JNJ-77242113 fo the treatment of moderate-to-severe plaque psoriasis: FRONTIER 1. Oral Presentation presented at: The 25th World Congress of Dermatology (WCD) Annual Meeting; July 3-8, 2023; Suntec, Singapore.
• Krueger J, Bissonnette R, Pinter A, et al. JNJ-77242113, a targeted oral peptide that binds the interleukin (IL)-23 receptor, inhibits IL-23 signaling in the skin of psoriasis (PsO) patients. Poster presented at: The Society for Investigative Dermatology (SID) Annual Meeting; May 15-18, 2024; Dallas, Texas.
• Armstrong A, Ferris L, Gerdes S, et al. Improvements in patient-reported symptoms and signs of moderate-to-severe psoriasis with JNJ-77242113: results of the FRONTIER 1 study. Poster presented at: The American Academy of Dermatology (AAD) Annual Meeting; March 8-12, 2024; San Diego, CA.
• Papp K, Ferris L, Pinter A, et al. Improvements in psoriasis area and severity index and in percent body surface area of psoriasis with JNJ-77242113: treat-to-target analyses in the FRONTIER 1 study. Poster presented at: The American Acedemy of Dermatology (AAD) Annual Meeting; March 8-12, 2024, San Diego, CA.
• Pinter A, Eyerich K, Paller A, et al. JNJ-77242113 treatment induces a strong systemic pharmacodynamic response versus placebo in serum samples of patients with plaque psoriasis: results from the phase 2, FRONTIER 1 study. Oral Presentation presented at: The 32nd Congress of the European Academy of Dermatology and Venereology (EADV); October 11-14, 2023; Berlin, Germany.
• Bissonnette R, Pinter A, Ferris L, et al. A phase 2, randomized, placebo-controlled, dose-ranging study of oral JNJ-77242113 for moderate-to-severe plaque psoriasis: efficacy of overall and scalp psoriasis responses from FRONTIER 1. Oral Presentation presented at: The 32nd Congress of the European Academy of Dermatology and Venereology (EADV); October 11-14, 2023; Berlin, Germany.

FRONTIER-2 - (NCT05364554)

Key Publication:

Ferris L, Bagel J, Huang Y, et al. FRONTIER-2: a phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dematol. 2025; 92:495-502.  

Related Presentations:

• Bonzehardt E, Cho Y, Xiong Y, et al. Exposure – response relationship of icotrokinra effects in participants with moderate-to-severe plaque psoriasis: phase 2b FRONTIER 1&2 results. Poster presented at: The Society for Investigative Dermatology (SID); May 7-10, 2025; San Diego, CA.
• Eyerich K, Ferris L, Krueger J, et al. JNJ-77242113 induces a strong and durable pharmacodynamic response in serum and skin of patients with moderate-to-severe psoriasis: 1-year results from FRONTIER 1 & 2. Poster presented at: The 10th International Congress Psoriasis from Gene to Clinic (G2C) meeting; December 5-7, 2024; London, UK.
• Ferris L, Gerdes S, Rich P, et al. Treatment satisfaction with JNJ-77242113 in patients with moderate-to-severe plaque psoriasis: 1-year results from the FRONTIER 1 & 2 Studies. Poster presented at: The European Academy of Dermatology and Venereology (EADV); September 25-28, 2024; Amsterdamn, the Netherlands.
• Armstrong A, Ferris L, Gerdes S, et al. Early and durable improvements in patient-reported symptoms and signs of moderate-to-severe psoriasis with JNJ-77242113: 1-year results from FRONTIER 1 & 2. Oral Presentation presented at: The European Academy of Dermatology and Venereology (EADV); September 25-28, 2024; Amsterdam, Netherlands.
• Papp K, Ferris L, Pinter A, et al. Sustained improvements in psoriasis area and severity index and in percent body surface area of psoriasis with JNJ-77242113 in patients with moderate-to-severe plaque psoriasis: treat-to-target analyses in the FRONTIER 1 & 2 studies. Poster presented at: The European Academy of Dermatology and Venereology (EADV); September 25-28, 2024; Amsterdam, Netherlands.
• Ferris L, Bagel J, Huang Y, et al. A phase 2b, long-term extension, dose-ranging study of oral JNJ-77242113 for the treatment of moderate-to-severe plaque psoriasis: FRONTIER-2. Oral Presentation presented at: The American Academy of Dematology (AAD) Annual Meeting; March 8-12, 2024; San Diego, CA.

Johnson & Johnson Phase 1 Clinical Studies

Key Publication:

Fourie A, Cheng X, Chang L, et al. JNJ-77242113, a highly potent, selective IL-23 receptor antagonist peptide, provides robust IL-23 pathway inhibition with oral dosing. Nat Sci Rep. 2024;14:17515.

Related Presentations:

• Fourie A, Cheng X, Chang L, et al. First-in-class oral peptide systemically targeting the IL-23 pathway. Oral Presentation presented at: The International Societies for Investigative Dermatology (ISID); May 10-13, 2023; Tokyo, Japan.

Other Publications or Presentations

Pharmacokinetics

Key Publication:

Knight B, Tammara B, Modi N, et al.Translational pharmacokinetics of icotrokinra, a targeted oral peptide that selectively blocks the interleukin-23 receptor and inhibits signaling. Dematol Ther. 2025;15:2495-2520.

Related Presentations:

• Baguet T, Tammara B, Odeja J, et al. Pharmacokinetic bridging of icotrokinra (JNJ-77242113) oral solution and tablet formulations. Poster presented at: The American Society for Clinical Pharmacology & Therapeutics (ASCPT); May 28-31, 2025; Washington, D.C.  
• Knight B, Dallas S, Mardirosian S, et al. ADME profiling of targeted oral peptide JNJ-77242113. Poster presented at: The American Society for Clinical Pharmacology & Therapeutics (ASCPT); May 28-31, 2025; Washington, D.C.

Bibliography Description

A literature search was conducted on January 13, 2026. For conference presentations from 2025-present, click on the first author for a direct hyperlink or copy the url into your browser (for US only). For other regions, and for reprints of citations that are not hyperlinked, please contact your local Medical Information department. To streamline this bibliography, some citations are not listed including, encore presentations, review articles, non- Johnson & Johnson sponsored conference presentations and some clinical studies that do not include United States study sites. The content hyperlinked from this bibliography is for personal use only and is subject to congress copyright permissions.